4 Biotech Penny Stocks To Watch Right Now – Including A Truly Psychedelic Stock
“Since we know small-cap stocks are hot and biotech stocks are as well, it might make sense to follow some smaller biotech penny stocks this month,”
“Since we know small-cap stocks are hot and biotech stocks are as well, it might make sense to follow some smaller biotech penny stocks this month,”
One-size-fits-all drugs are giving way to precision medicine, which the author of today’s article expects will come to dominate the health care marketplace in the next three to five years.
On Monday, the small biotech stock highlighted in today’s article hit a record high, skyrocketing 95.1%. The catalyst?
The small-cap biotech featured in today’s article has been on a wild trading ride in recent days, having surged 1,600% in two days on enthusiasm for its immunotherapy treatment for breast cancer, clinical trial results for which demonstrate 0% recurrence of the disease at a median of five years in patients who received the treatment following surgery and Herceptin treatment.
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential,” declares the author of today’s… Read More »5 Aggressive Tech Plays Under $10
November saw the FDA grant its first emergency use approval for an at-home, self-collected nasal swab test for COVID-19 and approve the first drugs for… Read More »These Biotechs Are Awaiting FDA Rulings In December
With potential COVID-19 vaccines and therapeutics garnering most of the attention this year in the biotech space, the biotech stock featured in today’s article, which has “a unique approach to the business of drug development” for genetic diseases, has been flying under the radar.
Hated stocks and biotech are the best bets right now.
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential.”
Among the three stocks highlighted in today’s article where analysts at RBC see upside potential over 100% – and which have all earned “Strong Buy” consensus analyst ratings – is “a pharmaceutical company with a unique niche.